Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04024254 · ClinicalTrials.gov registry record · Phase 4

A Study of Serum Folate Levels in Patients Treated With Olaparib

A Phase 4 study of Breast Cancer and Ovarian Cancer, sponsored by Rush University Medical Center.

Completed
Registry status
Phase 4
Development phase
10
Enrollment target
1
Study location

NCT04024254 is a Phase 4 study of Breast Cancer and Ovarian Cancer that has completed, run by Rush University Medical Center. The registered enrollment target is 10 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04024254, a Phase 4 study of Breast Cancer and Ovarian Cancer, has completed, sponsored by Rush University Medical Center.

COMPLETED
Registry status
Phase 4
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

This is a study investigating folate deficiency (lack of folic acid in the blood) in patients who take the drug olaparib to treat their advanced ovarian or breast cancer.

Interventions

  • DRUG Folic Acid Tablet

Study Locations (1)

Illinois

  • Rush University Medical Center - Chicago

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2020-07-21
Est. Completion 2025-12-31
Phase Phase 4

Sponsor

Rush University Medical Center

320 total trials

What the Registry Record Tells You About NCT04024254

The ClinicalTrials.gov registry entry for NCT04024254 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Folic Acid Tablet is the first listed.

NCT04024254 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT04024254 about?

NCT04024254 is a clinical study titled "A Study of Serum Folate Levels in Patients Treated With Olaparib". This is a study investigating folate deficiency (lack of folic acid in the blood) in patients who take the drug olaparib to treat their advanced ovarian or breast cancer.

What is the current status of trial NCT04024254?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2020-07-21. Estimated completion is 2025-12-31.

What conditions does trial NCT04024254 study?

This clinical trial studies the following conditions: Breast Cancer, Ovarian Cancer, Folic Acid Deficiency.

What interventions are being tested in trial NCT04024254?

The interventions under investigation include: Folic Acid Tablet (DRUG).

Who is sponsoring clinical trial NCT04024254?

This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04024254 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.